Reports Q4 revenue $54.4M excluding deferred revenue, consensus $47.8M. "Our full year 2022 results reflect the success we’ve seen with our first product and the investments we’ve made to execute on all of our strategic priorities, which position us well to become the category leader in diagnostic testing both in the home and at the point of care," said Ayub Khattak, Chairman and CEO of Cue Health. "From diagnostic testing to virtual care to the procurement of treatment for a range of infectious diseases as well as a growing menu of general health and wellness concerns, Cue has strengthened its integrated care platform to empower people to live their healthiest lives."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HLTH:
